Start your Trading & Investing Journey with us
Join our channel for Daily Free Trades with Live analysis on Youtube, Trade Setup with Important Levels, and Important Stock Market Updates
Mahamaya Lifesciences IPO Review - Issue Date, Price, GMP, Subscription, Allotment, Lot Size, and Details
Mahamaya Lifesciences IPO : Key Performance Indicators, PE Ratio, EPS, ROE, ROCE & RoNW
The Company Key Performance Indicates the pre-issue EPS of ₹
7.6 and post-issue EPS of ₹
6.68 for FY25. The pre-issue P/E ratio is
15.00x, while the post-issue P/E ratio is
17.06x against the Industry P/E ratio is
132x. The company's ROE for FY25 is
34.94% and RoNW is
26.19%. The Annualised EPS is ₹
8.48x and P/E is
13.45x. These metrics suggest that the IPO is fully priced.
Key Performance Indicator
| KPI | Values |
|---|---|
| EPS Pre IPO (Rs.) | 7.6 |
| EPS Post IPO (Rs.) | 5.53 |
| Adjusted 12M EPS Post IPO (Rs.) | 7.01 |
| P/E Pre IPO | 15.00 |
| P/E Post IPO | 20.61 |
| Adjusted 12M P/E Post IPO | 16.25 |
| ROE | 34.94% |
| ROCE | 23.15% |
| P/BV | 2.27 |
| Debt/Equity | 1.08 |
| RoNW | 26.19% |
| EBITDA Margin | 9.22% |
| PAT Margin | 4.84% |
© 2022 CA Abhay Varn. All Rights Reserved Abhayvarn.com
